Efficiency of application of sorbed probiotics in the complex therapy of pneumonia caused by SARS-CoV-2. Quality of life in the short term COVID-19
Q4 Social Sciences
E. Meskina, M. K. Khadisova, T. V. Stashko, L. Galkina, E. E. Tselipanova, I. M. Shilkina
{"title":"Efficiency of application of sorbed probiotics in the complex therapy of pneumonia caused by SARS-CoV-2. Quality of life in the short term COVID-19","authors":"E. Meskina, M. K. Khadisova, T. V. Stashko, L. Galkina, E. E. Tselipanova, I. M. Shilkina","doi":"10.33029/2305-3496-2022-11-3-69-80","DOIUrl":null,"url":null,"abstract":"Aim. To determine the clinical efficacy and safety of the immobilized (sorbed) probiotics Bifidobacterium bifidum 1 (5×108 CFU) and B. bifidum 1 (5×107 CFU) in combination with Lactobacillus plantarum 8P-А3 (5×107 CFU) in the complex therapy of pneumonia caused by SARS-CoV-2 in adult patients without severe risk factors and their impact on health-related quality of life (QoL). Material and methods. An open, randomized prospective study included 100 patients (45 males, 55 females), aged from18 to 60 years without risk factors for severe COVID-19, with pneumonia confirmed by computed tomography and an area of lung lesion no more than 75% (moderate forms). SARS-CoV-2 RNA in nasal and oropharyngeal swabs (RT-PCR) was detected in 72% of the participants, in the rest it was highiy probable in terms of the aggregate parameters. The publication presents the results of self-assessment (94 respondents) of working capacity limitations, shortness of breath, intestinal disorders since the end of the probiotic regimen (PR: hospitalization period – B. bifidum 1, 3 capsules 2 times a day for 10 days, then after hospitalization – B. bifidum 1 in combination with L. plantarum 8P-А3 2 powders 3 times a day for 14 days) and QoL (Short Form Medical Outcomes Study: SF-36) 1 month after hospitalization. Results. At the end of PR, the ability to engage in daily activities was higher by 23.1% [95% confidence interval 5.3–37.3, OR 0.08 (0.08–0.77)]. Difficulty of breathing during exercise was less common by 29.7% [15.1–44.5%], OR 0.09 [0.02–0.40], hard stools and no bowel movements were recorded less often by 21.3% [8.5–34, 1] for 1–3 days. One month after hospitalization, the QoL of the patients receiving standard treatment was significantly reduced relative to population indicators in Russia. It was more significantly due to the psychological component of health [total measurement 38.1 (36.2–40.0)] and less significantly due to the physical component [49.5 (48.3–50.8)]. The main reasons limiting daily activities [Role Emotional (RE): 39.4 (37.4–41.4)] were decreased vitality [VT: 40.2 (38.9–041.5)], emotional depression [Mental Health (MH): 41.2 (39.4–43.0)], deficit of social contacts [Social Functioning (SF): 45.1 (43.7–46.6)]. The patients who received PR had a higher ability to carry out daily activities [RE: 57.7 (55.6–59.7)], the severity of psychological problems associated with fatigue, anxiety and depression was lower [MH: 59.8 (58.7–60.9), р<0,001]. The effect of the PR on negative perceptions of social isolation was comparatively less [SF: 53.9 (52.2–55.4)]. The QoL of the patients who additionally suffered from diarrhea in the acute period of SARS-CoV-2 pneumonia was worse in comparison with the patients without diarrhea (due to pain and inability to endure physical activity). The effects of immobilized (sorbed) probiotics to the QoL of the patients with diarrhea during the acute period of COVID-19 were most significant. Conclusion. PR had a significant positive effect on the QoL within a month after hospitalization, increasing working capacity and improving mental health, reducing the severity of psychological problems and fatigue. Additional researches are needed on the possible relationship of organic and functional gastrointestinal diseases with the progression of diarrhea in patients infected with SARS-CoV-2. No side effects of the sorbed probiotics regimen have been identified. © Eco-Vector, 2022.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases: News, Opinions, Training","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33029/2305-3496-2022-11-3-69-80","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Social Sciences","Score":null,"Total":0}
引用次数: 0
Abstract
Aim. To determine the clinical efficacy and safety of the immobilized (sorbed) probiotics Bifidobacterium bifidum 1 (5×108 CFU) and B. bifidum 1 (5×107 CFU) in combination with Lactobacillus plantarum 8P-А3 (5×107 CFU) in the complex therapy of pneumonia caused by SARS-CoV-2 in adult patients without severe risk factors and their impact on health-related quality of life (QoL). Material and methods. An open, randomized prospective study included 100 patients (45 males, 55 females), aged from18 to 60 years without risk factors for severe COVID-19, with pneumonia confirmed by computed tomography and an area of lung lesion no more than 75% (moderate forms). SARS-CoV-2 RNA in nasal and oropharyngeal swabs (RT-PCR) was detected in 72% of the participants, in the rest it was highiy probable in terms of the aggregate parameters. The publication presents the results of self-assessment (94 respondents) of working capacity limitations, shortness of breath, intestinal disorders since the end of the probiotic regimen (PR: hospitalization period – B. bifidum 1, 3 capsules 2 times a day for 10 days, then after hospitalization – B. bifidum 1 in combination with L. plantarum 8P-А3 2 powders 3 times a day for 14 days) and QoL (Short Form Medical Outcomes Study: SF-36) 1 month after hospitalization. Results. At the end of PR, the ability to engage in daily activities was higher by 23.1% [95% confidence interval 5.3–37.3, OR 0.08 (0.08–0.77)]. Difficulty of breathing during exercise was less common by 29.7% [15.1–44.5%], OR 0.09 [0.02–0.40], hard stools and no bowel movements were recorded less often by 21.3% [8.5–34, 1] for 1–3 days. One month after hospitalization, the QoL of the patients receiving standard treatment was significantly reduced relative to population indicators in Russia. It was more significantly due to the psychological component of health [total measurement 38.1 (36.2–40.0)] and less significantly due to the physical component [49.5 (48.3–50.8)]. The main reasons limiting daily activities [Role Emotional (RE): 39.4 (37.4–41.4)] were decreased vitality [VT: 40.2 (38.9–041.5)], emotional depression [Mental Health (MH): 41.2 (39.4–43.0)], deficit of social contacts [Social Functioning (SF): 45.1 (43.7–46.6)]. The patients who received PR had a higher ability to carry out daily activities [RE: 57.7 (55.6–59.7)], the severity of psychological problems associated with fatigue, anxiety and depression was lower [MH: 59.8 (58.7–60.9), р<0,001]. The effect of the PR on negative perceptions of social isolation was comparatively less [SF: 53.9 (52.2–55.4)]. The QoL of the patients who additionally suffered from diarrhea in the acute period of SARS-CoV-2 pneumonia was worse in comparison with the patients without diarrhea (due to pain and inability to endure physical activity). The effects of immobilized (sorbed) probiotics to the QoL of the patients with diarrhea during the acute period of COVID-19 were most significant. Conclusion. PR had a significant positive effect on the QoL within a month after hospitalization, increasing working capacity and improving mental health, reducing the severity of psychological problems and fatigue. Additional researches are needed on the possible relationship of organic and functional gastrointestinal diseases with the progression of diarrhea in patients infected with SARS-CoV-2. No side effects of the sorbed probiotics regimen have been identified. © Eco-Vector, 2022.
吸附型益生菌在SARS-CoV-2型肺炎综合治疗中的应用效果短期内的生活质量
的目标。探讨固定化(吸附式)益生菌两歧双歧杆菌1 (5×108 CFU)和双歧双歧杆菌1 (5×107 CFU)联合植物乳杆菌8P-А3 (5×107 CFU)联合治疗无严重危险因素的成人SARS-CoV-2型肺炎的临床疗效和安全性及其对健康相关生活质量(QoL)的影响。材料和方法。一项开放、随机、前瞻性研究纳入100例患者(男性45例,女性55例),年龄18 - 60岁,无重症COVID-19危险因素,计算机断层扫描确诊肺炎,肺病变面积不超过75%(中度)。在72%的参与者中检测到鼻和口咽拭子(RT-PCR)中的SARS-CoV-2 RNA,在其余参与者中,就聚集参数而言,这是高度可能的。出版提供了自我评估的结果(94人)的工作能力的局限性,气短、肠道疾病结束以来的益生菌疗法(公关:住院期间- b . bifidum 1,3胶囊每天2次,10天,住院后- b . bifidum 1结合l .杆菌8 p -А3 2粉一天三次连续14天)和生命质量(简式医学研究结果:SF-36) 1月后住院治疗。结果。PR结束时,参与日常活动的能力提高了23.1%[95%置信区间5.3-37.3,OR 0.08(0.08 - 0.77)]。运动时呼吸困难发生率为29.7% [15.1-44.5%],OR为0.09[0.02-0.40],运动1 - 3天内出现硬便和无排便的发生率为21.3%[8.5 - 34,1]。住院1个月后,与俄罗斯人口指标相比,接受标准治疗的患者的生活质量明显降低。心理健康分量(总分38.1(36.2-40.0))显著高于生理健康分量(总分49.5(48.3-50.8)),生理健康分量(总分49.5(48.3-50.8)显著低于心理健康分量(总分38.1 - 40.0)。限制日常活动的主要原因[角色情绪(RE): 39.4(37.4-41.4)]是活力下降[VT: 40.2(38.9-041.5)]、情绪抑郁[心理健康(MH): 41.2(39.4 - 43.0)]、社会交往缺陷[社会功能(SF): 45.1(43.7-46.6)]。接受PR治疗的患者有较高的日常活动能力[RE: 57.7(55.6-59.7)],与疲劳、焦虑和抑郁相关的心理问题严重程度较低[MH: 59.8 (58.7-60.9), p < 0.001]。PR对社会孤立负面感知的影响相对较小[SF: 53.9(52.2-55.4)]。SARS-CoV-2肺炎急性期合并腹泻患者的生活质量较无腹泻患者差(由于疼痛和无法忍受体力活动)。以固定化(吸附)益生菌对急性期腹泻患者生活质量的影响最为显著。结论。PR对住院后1个月内的生活质量有显著的正向影响,增加了工作能力,改善了心理健康状况,减轻了心理问题的严重程度和疲劳程度。器质性和功能性胃肠道疾病与SARS-CoV-2感染患者腹泻进展的可能关系有待进一步研究。没有发现吸收益生菌方案的副作用。©Eco-Vector, 2022。
本文章由计算机程序翻译,如有差异,请以英文原文为准。